Quantum Biopharma (QNTM) Non Operating Investment Income (2019 - 2026)

Quantum Biopharma has reported Non Operating Investment Income for 8 years, with the latest figure at $7.0 million in Q1 2026.

• Quarterly Non Operating Investment Income rose 123.6% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.1 million (down 349.06% YoY) and the FY2025 annual result came in at -$11.9 million, down 11498.54% from the prior year.
• Non Operating Investment Income rose to $7.0 million in Q1 2026 per QNTM's latest filing, from -$23.8 million in the prior quarter.
• Over five years, Non Operating Investment Income peaked at $7.5 million in Q2 2025 and troughed at -$23.8 million in Q4 2025.
• A 5-year average of -$451287.1 and a median of $71889.0 in 2023 frame the typical range for Non Operating Investment Income.
• The widest YoY moves for Non Operating Investment Income: up 1690813.51% in 2025, down 17648.14% in 2025.
• Over 5 years, Non Operating Investment Income stood at -$898731.0 in 2022, then soared by 136.21% to $325467.0 in 2023, then slumped by 58.29% to $135746.0 in 2024, then plunged by 17648.14% to -$23.8 million in 2025, then surged by 129.2% to $7.0 million in 2026.
• According to Business Quant data, Non Operating Investment Income over the past three periods registered $7.0 million, -$23.8 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.